Skip to content

Latest edition: Thursday, November 12, 2026, 11:00 am

General information, not personal advice

GOOGL■ NeutralNov 12BRBY.L■ NeutralNov 12AKZA.AS■ NeutralNov 11ABN.AS▲ PositiveNov 11NVDA■ NeutralNov 10CO.PA■ NeutralNov 10BAS.DE■ NeutralNov 9UCG.MI■ NeutralNov 9VLA.PA■ NeutralNov 9VIRI.PA■ NeutralNov 8
Carnet de Séance

Les sociétés cotées, chaque jour au plus fort de la séance

Ratings over the last 30 days: 1 positive, 9 neutral, 0 negative

AKZA.ASNeutral

AkzoNobel, Axalta: UK regulator raises competition concerns

According to Boursorama, the $25bn merger between AkzoNobel and Axalta could weaken competition. The two groups have one week to respond to the UK authority's concerns.

By Yvan T., published

Illustration. Photo: 2780243 / Pixabay

The facts

According to Boursorama (11 November 2026, 08:39), the combination of AkzoNobel and Axalta, valued at $25bn, could reduce competition. The concern is attributed to the UK regulatory authority.

According to Boursorama (same day, 09:41), the two companies have one week to respond to these concerns. The extracts available to us are truncated. They do not specify which markets are targeted, what kind of responses are expected, or what will happen after the deadline.

Our take

Personal view: these two pieces of information show that the deal faces a regulatory obstacle, without saying whether it will be removed. A one-week deadline to respond is a procedural step. It does not tell us whether the authority will demand concessions, which ones, or whether it will block the deal.

The sources contain no share prices, no detailed financial terms, and no position from either group. They also do not say whether other regulators are examining the case. I therefore cannot justify a target price, and I do not put one forward. My view is neutral: the regulatory risk is real, but the information available is not enough to call it either way.

What to watch: the two groups’ response within the deadline, then the authority’s decision on the next steps in the procedure.

Risks to watch

The UK authority could impose heavy conditions, or even oppose the deal, which would call the logic of the merger into question. Conversely, limited concessions could remove the uncertainty faster than expected. Our analysis rests on two truncated extracts from Boursorama, and it may change with more complete information.

Sources

  1. La fusion entre AkzoNobel et Axalta, d'un montant de 25 milliards de dollars, pourrait affaiblir la concurrenc (Boursorama, 11/11/2026 08:39)
  2. AkzoNobel et Axalta disposent d'une semaine pour répondre aux préoccupations de l'autorité de régulation brita (Boursorama, 11/11/2026 09:41)

Information from these sources is summarised and rewritten. It has not been independently verified beyond cross-checking between sources; where the reliability of a piece of information is in doubt, the article says so.

Transparency

  • Author
    To be completed, Founder and author of the site, private investor.
  • Conflicts of interest
    On the publication date, holds no position in AkzoNobel. The site receives no payment from the companies it covers. The author refrains from any transaction in a stock covered 24 hours before and 48 hours after publication.
  • Method
    Compilation of public information from the day (sources listed above). The facts reported are kept separate from the analysis, which expresses the author's view. Full methodology.
  • Artificial intelligence
    Text written with an artificial intelligence tool from the sources cited and published automatically, without prior human review.
  • History

General information, not personalised investment advice: this article does not take your situation into account. Investing in shares carries a risk of capital loss. Past performance is not a reliable indicator of future performance. Read the full risk warning.